Taylor Schreiber - 12 May 2026 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: STTK
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2026, 06:05:13 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber

Key filing fact

Taylor Schreiber filed Form 4 for Shattuck Labs, Inc. (STTK) on 13 May 2026.

Key facts

This page summarizes Taylor Schreiber's Form 4 filing for Shattuck Labs, Inc. (STTK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 May 2026, 06:05.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001601942 Primary reporting owner

Schreiber Taylor

Relationship: Chief Executive Officer, Director
Address: C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN
Signature: /s/ Andrew R. Neill, Attorney-in-Fact for Taylor Schreiber
Signature date: 13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STTK transaction

Common Stock

Award

Transaction value
Shares: +25,610
Change %: +27%
Price: $1.08^*
Shares after: 122,222
Date: 12 May 2026
Ownership: Direct

STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,610,750
Date: 12 May 2026
Ownership: By Houghton Capital Holdings, LLC

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STTK transaction Derivative

Warrants (Right to Buy)

Options Exercise

Transaction value
Shares: -25,610
Change %: -100%
Price
Shares after: 0
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,610
Exercise price: $1.08
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the "Warrants") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677.

Footnote F2

The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.